HRMY News and Press, Harmony Biosciences Holdings Inc. From 02/21/24

U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY PR Newswire Prescription Drug User Fee Act date is June 21, 2024 PLYMOUTH MEETING, Pa. , Feb. 21, 2024 /PRNewswire/ -...

2024-02-20 15:12:56 ET More on Harmony Biosciences Harmony Biosciences: 4 Problems With Investing (Rating Downgrade) Harmony Biosciences says Q4 preliminary net product revenue was about $168M Seeking Alpha’s Quant Rating on Harmony Biosciences Histori...

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME PR Newswire PLYMOUTH MEETING, Pa. , Feb. 20, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that...

2024-02-18 06:39:11 ET Summary This article provides a monthly dashboard with aggregate industry metrics in the healthcare sector. Fast facts on IDNA, a thematic and volatile biotech ETF. We conclude with 10 healthcare stocks cheaper than their peers in February. ... ...

2024-02-12 09:28:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are many types of companies in the financial markets, firstly from different sectors, and secondly, they can vary according to their capitalization size. Their capitalization can go by va...

HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024 PR Newswire PLYMOUTH MEETING, Pa. , Feb. 8, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report four...

2024-01-26 15:33:29 ET Summary Alkermes plc expects to have additional results from the phase 1b proof-of-concept study, using ALKS-2680 for the treatment of patients with narcolepsy, in the 1st half of 2024. An update on the advancement of a phase 2 study, using ALKS-2680 for the...

2024-01-19 08:00:00 ET Summary The healthcare sector is overvalued by 12.5% based on 11-year averages. Nevertheless, the healthcare providers industry shows a good value score. iShares U.S. Healthcare ETF is an unattractive alternative to XLV. We look at 10 healthcare stocks c...

2024-01-08 11:21:05 ET More on Harmony Biosciences Harmony Biosciences: 4 Problems With Investing (Rating Downgrade) Seeking Alpha’s Quant Rating on Harmony Biosciences Historical earnings data for Harmony Biosciences For further details see: Harmo...

HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE PR Newswire WAKIX ® (pitolisant) Preliminary Net Revenue of ~$168 Million for Fourth Quarter ...